Skip to content

DOPAMED

Active
Private limited companyfounded 20242 yrs activeRogierlaan 403, 1030 Schaarbeek, BelgiumKBO/BCE: BE 1013.896.260
Summary

DOPAMED has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show negative equity (-€4,796) and a net result of -€4,796. Its solvency ranks better than 5% of 19918 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 1.0% (low).

Checked score

Score 2024
Axes
Profitability0
Solvency0
Growth-
Track record67
Bankruptcy probability, 12 months
1.0% Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.52; short-term debt: 191.7% and cash: 13.1% of total assets), and equity is negative.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
-91.7%
Return on assets
-91.7%
Age of the figures
21 mo
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2024 annual accounts show negative equity and a net loss.
NBB · annual accounts 2024
raises risk · Filed more than 90 days late
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 31-10-2025, 92 days past the deadline. Measured on financial year 2023: companies more than 90 days late are in an abnormal legal state today in 5.61% of cases, against 1.66% across all filers.
NBB · 1 filing
Deviation from the deadline
2024
92 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its 2024 accounts 92 days after the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 23 September 2024, DOPAMED was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2024.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2024

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2024, micro schema

Equity
-€4,796
Total assets
€5,229
Net result
-€4,796
Working capital
-€4,796

Turnover and EBIT margin not published: the micro schema does not require them.

Key figures and ratios
2024 value
Solvency
-91.7%
Current ratio
0.52
Debt to equity
-2.09
ROA
-91.7%
Debt
€10,025
Debt ≤ 1 year
€10,025
Staff costs
€14,239

Peer companies

Historical observation

Of the 7,663 companies that looked in July 2024 the way this one looks now, 8.2% went bankrupt within 24 months and 84% are still going.

  • Micro
  • 2 to 5 years old
  • negative equity
  • a loss of 10% of the balance sheet or more
8.2% went bankrupt
5.4% stopped otherwise
84% still going

A further 2.0% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 1.0% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 7,663 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2024 · 26 lines
Balance sheet Code2024
Assets
Total assets20/58€5,229
Current assets29/58€5,229
Amounts receivable within one year40/41€3,605
Trade receivables40€346
Other amounts receivable41€3,259
Cash at bank and in hand54/58€684
Deferred charges and accrued income490/1€940
Equity and liabilities
Total equity and liabilities10/49€5,229
Equity10/15-€4,796
Profit (loss) carried forward14-€4,796
Amounts payable17/49€10,025
Amounts payable within one year42/48€10,025
Trade debts44€6,342
Suppliers440/4€6,342
Taxes, remuneration and social security45€3,683
Taxes450/3€342
Remuneration and social security454/9€3,341
Income statement Code2024
Remuneration, social security and pensions62€14,239
Gross operating margin9900€9,451
Operating profit (loss)9901-€4,787
Financial charges65/66B€9
Recurring financial charges65€9
Profit (loss) for the period before taxes9903-€4,796
Profit (loss) for the period9904-€4,796
Profit (loss) for the period to be appropriated9905-€4,796
Appropriation of the result
Profit (loss) to be appropriated9906-€4,796
Line2024
Remuneration, social security and pensions62€14,239
Gross operating margin9900€9,451
Operating profit (loss)9901-€4,787
Financial charges65/66B€9
Recurring financial charges65€9
Profit (loss) for the period before taxes9903-€4,796
Profit (loss) for the period9904-€4,796
Profit (loss) for the period to be appropriated9905-€4,796
Line2024
Assets
Total assets20/58€5,229
Current assets29/58€5,229
Amounts receivable within one year40/41€3,605
Trade receivables40€346
Other amounts receivable41€3,259
Cash at bank and in hand54/58€684
Deferred charges and accrued income490/1€940
Equity and liabilities
Total equity and liabilities10/49€5,229
Equity10/15-€4,796
Profit (loss) carried forward14-€4,796
Amounts payable17/49€10,025
Amounts payable within one year42/48€10,025
Trade debts44€6,342
Suppliers440/4€6,342
Taxes, remuneration and social security45€3,683
Taxes450/3€342
Remuneration and social security454/9€3,341
Line2024
Profit (loss) for the period9904-€4,796
Operating cash flow (approximation)-€4,796

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2025
31-10
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 92 days late
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Schaarbeek · 1 establishment unit since 2024
seat establishment The establishment unit on the map
Ground area
225 m²
Building footprint
112 m²
Volume, LiDAR
1,344 m³
Parcel 21904B0433/00W003, Brussels · tallest building 16.0 m, ±4 floors. Linked by address, not a title deed.
2 companies at this address See who is registered here
1 establishment unit
DOPAMED
Rogierlaan 403, 1030 SchaarbeekGeneral medical practice
since 20242.364.289.678
1 parcel
Brussels 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
21904B0433/00W003 Brussels 225 m² 1 · 112 m² 16.0 m · 4 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector and region

This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 9,128 companies in sector 86210 we hold annual accounts for 6,335. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded23-09-2024
Fiscal year end31-12
Activities, NACEBEL 2025
86210General medical practice
86220Specialist medical practice
E-invoicing
Reachable via Peppol
Peppol ID 0208:1013896260
Registered 27-03-2026

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.